Overall, we report a critical regulatory miR-181a/PPFIA1/PARP1/NF-κB-P65/KIT axis in CML, and our preclinical study supports that targeted PPFIA1 and PARP1 may serve as a potential CML therapy. This evidence concerns the gene PPFIA1 and chronic myelogenous leukemia, BCR-ABL1 positive.